ArticleImmunity, inflammation and disease2025
Respiratory Syncytial Virus and COVID-19 in Hospitalized Adults in Spain: Clinical, Radiological Features and Antimicrobial Use.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antibiotic Use, Bacterial Co-Infection, and Antimicrobial Resistance in Adults Hospitalized with COVID-19, Influenza, or RSV: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Respiratory Syncytial Virus and COVID-19 in Hospitalized Adults in Spain: Clinical, Radiological Features and Antimicrobial Use.Immunity, inflammation and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLower respiratory tract infections (LRTIs) impose a significant global burden, with over 400 million cases annually. This study compares the clinical features of adults hospitalized with respiratory syncytial virus (RSV) and COVID-19, two viral pathogens with similar presentations but differing epidemiology.
methodsThis cross-sectional study analyzed 100 adult cases with PCR-confirmed RSV or COVID-19, admitted to the hospital from January 2022 to March 2023. Data on clinical, sociodemographic, radiological, treatment, and laboratory variables were extracted from records.
resultsBoth cohorts consisted of elderly patients (> 70 years) with multiple comorbidities. Notably, the RSV group had a higher prevalence of CHF (24% vs. 10%, p = 0.014) and COPD (29% vs. 9%, p = 0.001). Radiologically, 51% of RSV patients had normal findings, whereas 48% of COVID-19 patients exhibited bilateral pneumonia (p = 0.001). Antimicrobial treatment was administered to 75% of RSV patients compared to 41% of COVID-19 patients (p < 0.001). RSV patients had marginally higher leukocyte and neutrophil counts, while COVID-19 patients showed significantly elevated CRP, ferritin, LDH, ALT, and potassium levels.
conclusionsDistinct profiles were identified between hospitalized RSV and COVID-19 patients. RSV patients, mostly older with CHF and COPD, were more likely to receive antibiotics, possibly reflecting the lack of targeted therapies. In contrast, COVID-19 patients exhibited higher inflammation and lung involvement. These findings highlight the need to refine treatment protocols, enhance antimicrobial stewardship, and develop specific RSV therapies alongside preventive strategies for high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.